Method and system for treatment of biological tissue

• US 8,962,324 B2
• Filed: 06/13/2013
• Issued: 02/24/2015
• Est. Priority Date: 01/18/2006
• Status: Active Grant

• Current Assignee: Cormatrix Cardiovascular, Inc.
• Original Assignee: Cormatrix Cardiovascular, Inc.
• Inventors: Matheny, Robert G
• Primary Examiner(s): Tate, Chris R
• Assistant Examiner(s): White, Douglas F
• Application Number:
  US13/916,803
• Publication Number:
  US 20140370116A1
• Time in Patent Office: 621 Days
• Field of Search: None
• US Class Current: 435/395
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/38 Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component and a bioactive agent component. In a preferred embodiment, the ECM scaffold component comprises mesothelial tissue and the bioactive agent comprises a statin.

Claims

1. A composition for treating damaged biological tissue, comprising:

an extracellular matrix (ECM) composition comprising a bioremodelable component comprising acellular mesothelial tissue, said mesothelial tissue further comprising an exogenously added statin, said statin being linked to said mesothelial tissue, wherein, when said ECM composition is administered to damaged biological tissue, said statin interacts with said mesothelial tissue, wherein said ECM composition modulates inflammation of said damaged biological tissue and induces bioremodeling and regeneration of new biological tissue.

2. The composition of claim 1, wherein said ECM composition further comprises a fluidizing component selected from the group consisting of water and saline.

3. The composition of claim 1, wherein said statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.

4. The composition of claim 1, wherein, when said ECM composition is administered to damaged cardiovascular tissue, said statin interacts with said mesothelial tissue, wherein myofibroblast and stem cell migration is induced, differentiation of said stem cells into cardiomyocytes is induced, RhoA activation is restricted and matrix metalloprotinase (MMP) production is reduced in said cardiovascular tissue, wherein said ECM composition induces neovascularization and bioremodeling of said cardiovascular tissue.